Chorokbaem Healthcare Co Ltd Asset Resilience Ratio
Chorokbaem Healthcare Co Ltd asset resilience ratio. Chorokbaem Healthcare Co Ltd (118000) has an Asset Resilience Ratio of 0.11% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See defensive interval ratio of Chorokbaem Healthcare Co Ltd to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Chorokbaem Healthcare Co Ltd (2013–2025)
Asset resilience ratio of Chorokbaem Healthcare Co Ltd from 2013 to 2025. This chart shows how Chorokbaem Healthcare Co Ltd's Asset Resilience Ratio has changed over time. Read Chorokbaem Healthcare Co Ltd total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Chorokbaem Healthcare Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Chorokbaem Healthcare Co Ltd total assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 0% |
| Short-term Investments | ₩272.30 Million | 0.11% |
| Total Liquid Assets | ₩272.30 Million | 0.11% |
Asset Resilience Insights
- Limited Liquidity: Chorokbaem Healthcare Co Ltd maintains only 0.11% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Chorokbaem Healthcare Co Ltd Industry Peers by Asset Resilience Ratio
Compare Chorokbaem Healthcare Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Novartis AG
MX:NVSN |
Drug Manufacturers - General | 0.08% |
|
AstraZeneca PLC
NYSE:AZN |
Drug Manufacturers - General | 0.06% |
|
AstraZeneca PLC
LSE:AZN |
Drug Manufacturers - General | 0.06% |
|
Yifan Xinfu Pharmaceutical Co Ltd
SHE:002019 |
Drug Manufacturers - General | 0.53% |
|
Dimed S.A. Distribuidora de Medicamentos
SA:PNVL3 |
Drug Manufacturers - General | 6.34% |
|
Firebrick Pharma Ltd
AU:FRE |
Drug Manufacturers - General | 0.29% |
|
Eli Lilly and Company
SA:LILY34 |
Drug Manufacturers - General | 6.46% |
|
Pfizer Inc
SA:PFIZ34 |
Drug Manufacturers - General | 5.33% |
Chorokbaem Healthcare Co Ltd Asset Resilience Ratio by Year (2013–2025)
Chorokbaem Healthcare Co Ltd asset resilience ratio by year from 2013 to 2025. The table below shows the annual Asset Resilience Ratio data for Chorokbaem Healthcare Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 0.11% | ₩225.32 Million ≈ $152.70K |
₩197.96 Billion ≈ $134.16 Million |
+0.08pp |
| 2024-12-31 | 0.03% | ₩55.00 Million ≈ $37.27K |
₩157.82 Billion ≈ $106.95 Million |
-1.46pp |
| 2023-12-31 | 1.49% | ₩2.32 Billion ≈ $1.57 Million |
₩155.30 Billion ≈ $105.25 Million |
+0.83pp |
| 2022-12-31 | 0.67% | ₩1.27 Billion ≈ $858.83K |
₩189.86 Billion ≈ $128.66 Million |
+0.10pp |
| 2020-12-31 | 0.57% | ₩787.10 Million ≈ $533.41K |
₩138.29 Billion ≈ $93.72 Million |
-17.34pp |
| 2019-12-31 | 17.91% | ₩12.50 Billion ≈ $8.47 Million |
₩69.80 Billion ≈ $47.31 Million |
+16.05pp |
| 2018-12-31 | 1.86% | ₩1.14 Billion ≈ $773.15K |
₩61.44 Billion ≈ $41.64 Million |
-0.49pp |
| 2017-12-31 | 2.35% | ₩863.06 Million ≈ $584.89K |
₩36.74 Billion ≈ $24.90 Million |
-35.20pp |
| 2016-12-31 | 37.55% | ₩10.83 Billion ≈ $7.34 Million |
₩28.84 Billion ≈ $19.55 Million |
+36.97pp |
| 2015-12-31 | 0.58% | ₩94.51 Million ≈ $64.05K |
₩16.41 Billion ≈ $11.12 Million |
-4.36pp |
| 2014-12-31 | 4.94% | ₩972.03 Million ≈ $658.73K |
₩19.67 Billion ≈ $13.33 Million |
-3.14pp |
| 2013-12-31 | 8.08% | ₩1.77 Billion ≈ $1.20 Million |
₩21.97 Billion ≈ $14.89 Million |
-- |
About Chorokbaem Healthcare Co Ltd
METACARE CO., Ltd. distributes pharmaceuticals and medical devices in South Korea. The company sells orthopedic medical devices and consumables; and provides pharmaceutical integration and professional logistics services. It is involved in investment advisory. The company was formerly known as SMEDI Co., Ltd. and changed its name to METACARE CO., Ltd. in August 2024. METACARE CO., Ltd. was founde… Read more